Enveda, a clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life's chemistry, today announced three major milestones: the close of its $150 million oversubscribed Series D financing, enrolling of the first patient in a Phase 1b clinical trial for lead program ENV-294 in atopic dermatitis, and the appointment of former Pfizer Chief Scientific Officer and President of Worldwide R&D, Dr. Mikael Dolsten, to its Board of Directors.

The round was led by Premji Invest with participation from new and existing investors Baillie Gifford, Kinnevik, Lingotto Investment Management, Peakline Partners, FPV, Socium Ventures, Dimension, Level Ventures, Henry Kravis, IA Ventures, and Lux Capital. This follows a $150 million Series C closing in February that included Sanofi, bringing the company's total funding to $517 million.

Enveda is a biotechnology company that learns from life's chemistry to create better medicines faster. Enveda uses AI-powered tools to identify and characterize a wide range of molecules produced by living organisms, the vast majority of which have never been explored by science, creating a database of chemical biodiversity: the library of life. By growing, organizing, translating, and searching this unique library, Enveda learns from life's evolved solutions to address today's most pressing medical needs.